Tricida Inc. announced results from its pivotal Phade 3 clinical trial for TRCA-301 in 217 chronic kidney disease patients with metabolic acidosis.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Merck & Co. Inc. said long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment.
Mixed results were reported from closely watched studies combining Bristol-Myers Squibb’s cancer immunotherapy Opdivo with Nektar Therapeutics’ experimental drug NKTR-214.
Merck & Co.’s immunotherapy Keytruda improved survival as a stand-alone treatment for newly diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer.
Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can safely skip chemotherapy after tumor removal, U.S. researchers said.
In a disappointment for Roche Holding, two of its oncology drugs provided only modest protection from disease progression in lung cancer and breast cancer, according to data from separate clinical trials.
Janssen, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray in patients with treatment-resistant depression.
Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.
AstraZeneca’s first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Novo Nordisk said data from a large final-stage study of a pill the company hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim’s established Jardiance.
Genmab and J&J’s Janssen division pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced or metastatic NSCLC.
Roche’s bid to keep Merck’s cancer blockbuster Keytruda within striking distance got a lift when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients’ survival.
AstraZeneca’s immunotherapy drug Imfinzi hit a second important goal by improving overall survival in lung cancer patients.
Merck & Co.’s cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer.
Shares of newly dubbed Sesen Bio plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer trial.
Nabriva Therapeutics Plc’s potential new antibiotic to treat a common form of pneumonia met the main goal of a key clinical trial.
Roche’s recently launched medicine Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed.
Johnson & Johnson’s Janssen division decided to end clinical trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.
Genentech, a Roche company, released follow-up data from its Phase III ALEX trial comparing its Alecensa (alectinib) to Pfizer’s Xalkori (crizotinib) in late-stage non-small cell lung cancer.
AstraZeneca’s first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).